Published • loading... • Updated
Retail Giants Battle to Become America’s Top GLP-1 Destination
CEO Brian Moynihan says the bank sees the expense as a worthwhile investment and is negotiating lower prices with drugmakers and pharmacy benefit managers.
Summary by South Florida Reporter
10 Articles
10 Articles
The US bank invests heavily in GLP-1 preparations for its employees and sees this as a worthwhile investment in the workforce.
·Vienna, Austria
Read Full Article
Bank of America spends more than $250 million a year to cover the cost of GLP-1 medicines for weakening its employees, considering that the investment will reduce long-term medical expenses and improve staff health, CNBC says.
Bank of America CEO Says The Company Spends $250 Million A Year on GLP-1 Drugs for Their Employees. He Calls It a Good Investment
Bank of America CEO Brian Moynihan said the company has dramatically increased its investment in medications such as Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Zepbound.
·New York, United States
Read Full Article
Business InsiderReposted by 
The New York Ledger
The New York LedgerBank of America spends more than $250 million on GLP-1s
Open the article to view the coverage from Business Insider
·New York, United States
Read Full Article
Coverage Details
Total News Sources10
Leaning Left3Leaning Right2Center3Last UpdatedBias Distribution38% Left, 37% Center
Bias Distribution
- 38% of the sources lean Left, 37% of the sources are Center
38% Left
L 38%
C 37%
R 25%
Factuality
To view factuality data please Upgrade to Premium
